Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

证券研究报告：医药生物|行业周报 发布时间：2025-05-19 行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 7401.23 | | --- | --- | --- | | 52 | 周最高 | 8490.25 | | 52 | 周最低 | 6070.89 | 行业相对指数表现 2024-05 2024-07 2024-10 2024-12 2025-03 2025-05 -21% -17% -13% -9% -5% -1% 3% 7% 11% 15% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:陈成 SAC 登记编号:S1340524020001 Email:chencheng@cnpsec.com 近期研究报告 《医药 2024&2025Q1 总结——关注现 金流、盈利能力优先改善品种》 - 2025.05.15 医药生物行业报告 （2025.05.12-2025.05.18） 特朗普计划降低美国药品价格，CXO 企业有望受益 l 一周观点 ...

Group 1 - The third Advanced Technology Achievement Transformation Conference took place in Suzhou, showcasing over 1,500 companies across various industry clusters [1] - A micro drone resembling a thermos was displayed by Suzhou Lanjun Technology, capable of being controlled by a ground station to perform inspection and photography tasks [1] - AI glasses designed for the visually impaired were presented, featuring radar obstacle avoidance and real-time voice broadcasting capabilities [2] Group 2 - A digital gait assessment and training robot was introduced by Guanyi Medical, integrating AI and virtual reality to analyze gait data and assist in rehabilitation [2] - A nuclear technology application for kitchen waste resource utilization was demonstrated by Zhongke Tongchuang, converting organic waste into organic fertilizer efficiently [3]

资金从何而起 [Table_Authors] 吴信坤(分析师) ——港股资金跟踪新范式 1 本报告导读： ①基于属地来源和历史交易行为的"两步法"核心框架将港股资金面拆分为长短线 外资、内资、港资等各类资金。②拆分后资金存量规模显著分化，过去以来外资占 比虽下滑但仍延续主导，南向定价权边际提升。③长短线外资在交易的换手频率和 方向变动上存在差异，南向通常会逆势买入，近期外资流出而南向流入的格局仍延 续。 投资要点： 登记编号 S0880525040084 陆嘉瑞(研究助理) 021-38676666 登记编号 S0880125042248 风险提示：部分资金数据为估算值，与真实情况或有出入。 策 略 研 究 策略研究 /[Table_Date] 2025.05.17 2025-05-18 请务必阅读正文之后的免责条款部分 海 外 策 略 研 究 证 券 研 究 报 告 021-38676666 登记编号 S0880525040061 余培仪(分析师) 021-38676666 [Table_Summary] 基于历史交易行为辨别外资属性的核心框架。通常而言，微观资金 面的跟踪源自各类投资者资金流动的汇总，港股 ...

瑞星久宇燃气新研发中心，工人正在安装设备。 国药天域智谷项目效果图。 项目启动两年后，GE医疗中国精准医疗产业基地(一期)项目完工，将推动高端装备国产化和精准医疗的 创新发展； 去年启动的项目，瑞星久宇燃气设备(成都)有限公司新研发中心，预计下月投用，将进一步推进燃气设 备产品的更新换代，提升产品的市场占有率； 还有刚刚开工建设的国药天域智谷项目，瞄准发展医疗大健康、电子信息、装备制造、新型材料，预计 2027年上半年实现整体交付…… 今年以来，成都坚持项目为王，围绕产业化项目招引促建创新机制、拓展渠道、做优服务，推动招引项 目加快建设、落地转化。通过构建项目"招引—开工—投运"全生命周期服务体系，创造条件推动项 目"签约即拿地""拿地即开工"；依托"投资盖碗茶"品牌活动，实施全要素保障和全流程跟踪服务，推动 项目建设倒排工期、超预期建设，跑出加快落地、投产投用加速度。 聚焦核医学关键设备制造 精准医疗产业基地一期完工 近日，GE医疗中国精准医疗产业基地项目传来新进展，该项目一期工程完工。项目建成后，将推动高 端装备国产化和精准医疗的创新发展，为中国医患的精准诊治提供服务。 GE医疗是全球精准医疗创新头部企业 ...

Group 1 - The Chinese government is focusing on expanding inbound consumption, as highlighted in the 2025 government work report, with ongoing policy benefits being released [2] - The number of foreign visitors entering and exiting China during the May Day holiday reached 1.115 million, a 43.1% increase compared to the previous year, with 380,000 entering under visa exemption policies, marking a 72.7% increase [4] - GE Healthcare plans to invest 500 million RMB in its MRI headquarters in Tianjin over the next five years, emphasizing the market vitality and innovation prospects in China [4][5] Group 2 - Airbus is building a second assembly line for the A320 series in Tianjin, expected to be operational by early 2026, indicating the company's recognition of China's market potential [7] - Tesla achieved a record sales figure of over 650,000 electric vehicles in mainland China in 2024, showcasing the demand for American brands in the Chinese market [7] - Saudi Aramco's cumulative investment in China is expected to exceed 200 billion RMB by 2024, reflecting the stable investment environment and considerable returns provided by China's large-scale market and resilient supply chain [7]

Group 1 - The core viewpoint of the article indicates that the domestic medical equipment market is beginning to recover, with significant growth in procurement amounts observed in the first four months of the year, and an expected increase in equipment updates starting from Q4 2024 [2][3] - In the first quarter report, the company reported a revenue of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit attributable to shareholders of 8.07 million yuan, down 91.94% year-on-year [2] - The company anticipates rapid revenue growth from its new product lines in minimally invasive surgery and cardiovascular intervention by 2025, which is expected to alleviate profit pressure [2] Group 2 - The company noted that while large-scale procurement plans for medical equipment updates have been announced across provinces for 2024, the actual implementation and final bidding rates are low, with remaining projects expected to be executed in 2025 [3] - The company is responding to the trend of lower winning bid prices in some procurement projects, which may signal a decline in overall industry gross margins, by focusing on high-end products and investing heavily in R&D [3] - The increase in centralized procurement projects is expected to accelerate industry consolidation, with leading brands gaining more market share and domestic brands also increasing their market presence [3]

Core Viewpoint - The medical equipment procurement amount in terminal hospitals has significantly increased in the first four months of this year, indicating a rapid recovery in the industry, with companies like Kaili Medical expressing confidence in returning to a growth trend [1][2]. Industry Summary - The total budget for medical equipment in Guizhou Province exceeds 578 million, and Hebei Province has made a one-time procurement of 79 ultrasound devices, indicating a reshaping of the domestic medical equipment market [1]. - The shift from "following" to "leading" in various segments by Chinese medical equipment manufacturers is becoming more pronounced [1]. - The procurement policies are expected to lead to a significant increase in the volume of equipment purchased, with a three-year cycle for equipment updates anticipated to boost sales [2]. Company Summary - Kaili Medical, which started with ultrasound equipment and expanded into endoscopy, is now a leading domestic player in soft endoscopes, with market share second only to Olympus and Fujifilm [2]. - In Q1 2024, Kaili Medical reported revenue of 430 million and a net profit of 8.07 million, both showing a decline, but there are signs of recovery with procurement activities picking up [2][3]. - The company has seen a significant increase in successful bids, with expectations for a "low first half, high second half" performance in 2024 [3]. - The recent collective procurement results in Hainan Province showed a budget of 190 million for 200 ultrasound devices, with a savings rate exceeding 37%, indicating a trend towards cost-effective procurement [3]. - Kaili Medical's dual business model of "ultrasound + endoscopy" is now stable, with optimistic growth projections for new business areas like minimally invasive surgery and cardiovascular intervention [5]. - The company has invested heavily in R&D, with 473 million allocated in 2024, representing 23.48% of revenue, and a 23.7% increase in R&D expenses in Q1 2025 [7].

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology industry, suggesting it is at a turning point for profit improvement and has high allocation value [3][4]. Core Insights - The pharmaceutical sector is showing signs of recovery after three years of declining profitability, with a notable increase in net profit margin by 0.3% in Q1 2025 compared to the previous year [3][5]. - Key sub-sectors such as CXO, innovative drugs, biological products, private hospitals, and medical consumables have demonstrated strong performance in Q1 2025, with several leading companies exceeding expectations [3][4]. - The report recommends focusing on sub-sectors and companies with clear upward trends in performance, including innovative drugs and CXO services [3][4]. Overall Performance of the Sector - In 2024, 473 A-share pharmaceutical companies achieved total revenue of 24,588 billion yuan, a year-on-year decrease of 0.9%, and a net profit of 1,412 billion yuan, down 12.1% [3][5]. - For Q1 2025, the sector reported revenue of 6,104 billion yuan, a decline of 4.2% year-on-year, with net profit at 487 billion yuan, down 8.7% [3][5]. Sub-sector Performance - The CXO sector has shown a turnaround since Q4 2024, with Q1 2025 revenue of 225 billion yuan, reflecting an 11.6% year-on-year increase, and net profit of 50 billion yuan, up 72.8% [3][23]. - The innovative drug sector continues to grow rapidly, with leading companies like Heng Rui Medicine and Bai Jie Shen Zhou performing above expectations [3][18]. - The hospital sector is beginning to show signs of recovery, with Q1 2025 revenue of 144 billion yuan, a year-on-year increase of 4.9%, and net profit of 11 billion yuan, up 19.2% [3][28]. Investment Analysis - The report emphasizes the importance of investing in sectors and companies that are showing clear signs of upward trends, particularly in innovative drugs and CXO services [3][4]. - Specific companies recommended for investment include Heng Rui Medicine, Bai Jie Shen Zhou, and Wu Xi AppTec in the innovative drug and CXO sectors [3][4].

Group 1 - China State Construction signed new contracts totaling 1.52 trillion yuan from January to April, representing a year-on-year increase of 2.8% [1] - Yongpu Medical's subsidiary obtained a medical device business license valid until May 7, 2030, allowing it to engage in medical device retail and wholesale [1] - Ningbo Maritime received a government subsidy of 4.42 million yuan, which will impact its net profit for the fiscal year 2025 [1] Group 2 - Mingpu Optoelectronics obtained a patent for a magnetic powder core and its preparation method, enhancing its capabilities in magnetic materials technology [1] - Digital Zhitong plans to establish a wholly-owned subsidiary in Beijing with a registered capital of 5 million yuan [1] - Zhongmin Energy's shareholder plans to reduce its stake by up to 0.28% of the company's total shares [1][6] Group 3 - Tunnel Holdings' controlling shareholder intends to increase its stake in the company by investing between 250 million to 500 million yuan [1] - China Telecom appointed Liu Guiqing as the new President and COO [1] - Datang Power completed the issuance of 3 billion yuan in medium-term notes, with proceeds aimed at repaying debt and supplementing working capital [1] Group 4 - *ST Weihai won a bid for a flood control project worth 182 million yuan, accounting for 7.35% of its audited revenue for 2024 [1] - Huijin Tong announced a cash dividend of 0.0868 yuan per share, totaling 29.44 million yuan [1] - Xinkai Energy's shareholders plan to reduce their holdings by a combined total of 4% of the company's shares [1][39] Group 5 - Xinhuan Group's subsidiary won a 1.02 billion yuan nuclear power project contract [1] - Southern Airlines reported a 12.14% year-on-year increase in passenger turnover for April [1] - Xinjiang Torch plans to acquire 100% equity of Yushan Litai for 125 million yuan [1]